胆管癌（CCA）市場 - 市場の洞察、疫学、市場予測：2032年

主要7ヶ国における胆管癌（CCA）の市場規模は、2021年に7億8,610万米ドルとなりました。同市場は、予測期間（2019年～2032年）にかけてさらに拡大すると予測されています。

当レポートでは、主要7ヶ国における胆管癌（CCA）市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2032年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 主な洞察

第2章 胆管癌（CCA）のエグゼクティブサマリー

第3章 胆管癌（CCA）市場概要

第4章 胆管癌（CCA）：疾患の背景と概要

• イントロダクション
• 胆管癌（CCA）
• 胆管癌の症状
• 胆管癌の分類
• 肝内胆管癌の分子病態
• 胆管癌の診断
  • CCAの診断アルゴリズム
  • 肝内胆管癌（ICCA）の病期分類

第5章 治療

• 胆管癌の治療アルゴリズム
• 胆管癌治療ガイドライン
• 国際肝臓癌協会（ILCA）のICCA治療ガイドライン
• NCCN臨床診療ガイドライン- 肝胆道癌（バージョン5.2020）

第6章 疫学と患者数

• 主な調査結果
• 疫学の調査手法
• 主要7ヶ国における胆管癌（CCA）の発生例

第7章 米国の疫学

第8章 欧州5ヶ国の疫学

第9章 日本の疫学

第10章 患者動向

第11章 胆管癌試験における主要なエンドポイント

第12章 上市済み薬剤

第13章 新たな治療法

第14章 コンジョイント分析

第15章 胆管癌（CCA）：主要7ヶ国市場分析

• 主な調査結果
• 市場の見通し
• 主要7ヶ国における胆管癌（CCA）の市場規模
• 米国における胆管癌（CCA）の総市場規模
• 欧州5ヶ国における胆管癌（CCA）の総市場規模
• 日本における胆管癌（CCA）の総市場規模

第16章 市場アクセスと償還

第17章 KOL の見解

第18章 市場の促進要因

第19章 市場の抑制要因

第20章 SWOT分析

第21章 アンメットニーズ

第22章 付録

第23章 DelveInsightのサービス内容

第24章 免責事項

第25章 DelveInsightについて

List of Tables

• Table 1: Summary of Cholangiocarcinoma (CCA), Market, Epidemiology, and Key Events (2019-2032)
• Table 2: Gross features of Cholangiocarcinoma
• Table 3: Classification of CCA
• Table 4: Molecular alterations in CCA
• Table 5: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
• Table 6: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
• Table 7: Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2019-2032)
• Table 9: Type-specific Incident Cases of CCA in the 7MM (2019-2032)
• Table 10: Age-specific Incident Cases of CCA in the 7MM (2019-2032)
• Table 11: Stage-specific Incident Cases of CCA in the 7MM (2019-2032)
• Table 12: Biomarker-specific Incident Cases of CCA in the 7MM (2019-2032)
• Table 13: Incident Cases of Cholangiocarcinoma (CCA) in the US (2019-2032)
• Table 14: Type-specific Incident Cases of CCA in the US (2019-2032)
• Table 15: Age-specific Incident Cases of CCA in the US (2019-2032)
• Table 16: Stage-specific Incident Cases of CCA in the US (2019-2032)
• Table 17: Biomarker-specific Incident Cases of CCA in the US (2019-2032)
• Table 18: Incident Cases of Cholangiocarcinoma (CCA) in EU-5 (2019-2032)
• Table 19: Type-specific Incident Cases of CCA in EU-5 (2019-2032)
• Table 20: Age-specific Incident Cases of CCA in EU-5 (2019-2032)
• Table 21: Stage-specific Incident Cases of CCA in EU-5 (2019-2032)
• Table 22: Biomarker-specific Incident Cases of CCA in EU-5 (2019-2032)
• Table 23: Incident Cases of Cholangiocarcinoma (CCA) in Japan (2019-2032)
• Table 24: Type-specific Incident Cases of CCA in Japan (2019-2032)
• Table 25: Age-specific Incident Cases of CCA in Japan (2019-2032)
• Table 26: Stage-specific Incident Cases of CCA in Japan (2019-2032)
• Table 27: Biomarker-specific Incident Cases of CCA in Japan (2019-2032)
• Table 28: Recommendations of cholangiocarcinoma; Practice guidelines; Diagnosis and management
• Table 29: Pemigatinib, Clinical Trial Description, 2022
• Table 30: Entrectinib, Clinical Trial Description, 2022
• Table 31: Ivosidenib, Clinical Trial Description, 2022
• Table 32: Comparison of emerging drugs under development
• Table 33: Comparison of emerging drugs under development (Continued)
• Table 34: Comparison of emerging drugs under development (Continued)
• Table 35: Comparison of emerging drugs under development (Continued)
• Table 36: Imfinzi, Clinical Trial Description, 2022
• Table 37: Melphalan, Clinical Trial Description, 2022
• Table 38: Derazantinib, Clinical Trial Description, 2022
• Table 39: E7090, Clinical Trial Description, 2022
• Table 40: Futibatinib, Clinical Trial Description, 2022
• Table 41: TT-0040 Clinical Trial Description, 2022
• Table 42: Market Size of CCA in the 7MM in USD Million (2019-2032)
• Table 43: Market Size of CCA by therapies in the 7MM, in USD Million (2019-2032)
• Table 44: Key market forecast assumptions for Imfinzi (durvalumab)
• Table 45: Key market forecast assumptions for Melphalan
• Table 46: Key market forecast assumptions for Derazantinib
• Table 47: Key market forecast assumptions for TT-0040
• Table 48: Key market forecast assumptions for futibatinib
• Table 49: Key market forecast assumptions for E7090
• Table 50: The US Market Size of CCA in USD Million (2019-2032)
• Table 51: Market Size of CCA by therapies in the US, in USD Million (2019-2032)
• Table 52: EU-5 Market Size of CCA in USD Million (2019-2032)
• Table 53: Market Size of CCA by therapies in EU-5 in USD Million (2019-2032)
• Table 54: Japan Market Size of CCA in USD Million (2019-2032)
• Table 55: Market Size of CCA by therapies in Japan, in USD Million (2019-2032)

List of Figures

• Figure 1: Cholangiocarcinoma
• Figure 2: Cholangiocarcinoma - anatomical classification
• Figure 3: Gross features of cholangiocarcinoma
• Figure 4: Symptoms of CCA
• Figure 5: Summary of key molecular alterations involved in CCA carcinogenesis
• Figure 6: Algorithm for management and diagnosis of Cholangiocarcinoma
• Figure 7: Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2019-2032)
• Figure 8: Incident Cases of Cholangiocarcinoma (CCA) in the US (2019-2032)
• Figure 9: Type-specific Incident Cases of CCA in the US (2019-2032)
• Figure 10: Age-specific Incident Cases of CCA in the US (2019-2032)
• Figure 11: Stage-specific Incident Cases of CCA in the US (2019-2032)
• Figure 12: Biomarker-specific Incident Cases of CCA in the US (2019-2032)
• Figure 13: Incident Cases of Cholangiocarcinoma (CCA) in EU-5 (2019-2032)
• Figure 14: Type-specific Incident Cases of CCA in EU-5 (2019-2032)
• Figure 15: Age-specific Incident Cases of CCA in EU-5 (2019-2032)
• Figure 16: Stage-specific Incident Cases of CCA in EU-5 (2019-2032)
• Figure 17: Biomarker-specific Incident Cases of CCA in EU-5 (2019-2032)
• Figure 18: Incident Cases of Cholangiocarcinoma (CCA) in Japan (2019-2032)
• Figure 19: Type-specific Incident Cases of CCA in Japan (2019-2032)
• Figure 20: Age-specific Incident Cases of CCA in Japan (2019-2032)
• Figure 21: Stage-specific Incident Cases of CCA in Japan (2019-2032)
• Figure 22: Biomarker-specific Incident Cases of CCA in Japan (2019-2032)
• Figure 23: Basic Treatment Division
• Figure 24: Signaling pathways involved in intrahepatic cholangiocarcinoma and the corresponding molecular therapies
• Figure 25: An approach to the management of CCA involves an initial assessment of its resectability
• Figure 26: A suggested treatment algorithm for patients with CCA
• Figure 27: Unmet Needs of cholangiocarcinoma (CCA)
• Figure 28: Market Size of CCA in the 7MM in USD Million (2019-2032)
• Figure 29: Market Size of CCA by therapies in the 7MM in USD Million (2019-2032)
• Figure 30: Market Size of CCA in the US, USD Millions (2019-2032)
• Figure 31: Market Size of CCA by Therapies in the US in USD Million (2019-2032)
• Figure 32: Market Size of CCA in EU-5, USD Millions (2019-2032)
• Figure 33: Market Size of CCA by Therapies in EU-5 in USD Million (2019-2032)
• Figure 34: Market Size of CCA in Japan, USD Millions (2019-2032)
• Figure 35: Market Size of CCA by Therapies in Japan in USD Million (2019-2032)

DelveInsight's "Cholangiocarcinoma (CCA) - Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cholangiocarcinoma, historical and forecasted epidemiology as well as the Cholangiocarcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Cholangiocarcinoma market report provides current treatment practices, emerging drugs, cholangiocarcinoma market share of the individual therapies, current and forecasted cholangiocarcinoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current cholangiocarcinoma treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States

• EU-5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2019-2032.

Cholangiocarcinoma (CCA) Understanding and Treatment Algorithm

The DelveInsight's Cholangiocarcinoma epidemiology report gives a thorough understanding of Cholangiocarcinoma. Cholangiocarcinoma is a type of cancer that forms in the slender tubes (bile ducts) that carry the digestive fluid bile. Bile ducts connect your liver to your gallbladder and to your small intestine. Cholangiocarcinoma (CCA) tumors can arise from anywhere in the biliary tract and may be difficult to identify based on histopathologic analysis alone. CCA can be anatomically differentiated into intrahepatic CCA (ICC) and extrahepatic CCA (ECC).

Early research on the genetic pathophysiology of CCAs concentrated on determining the carcinogenic function of certain genes, which were frequently discovered to be mutated in other cancers or altered by copy number changes. Studies have demonstrated that the genetic profiles of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma are diverse; in fact, 50% of patients have actionable mutations such as FGFR, IDH1, HER2, and BRAF.

For a definitive diagnosis, patients usually undergo endoscopic retrograde cholangiopancreatography and procedures such as cytology, brushing, FISH (fluorescence in situ hybridization)-polisomy, biopsy, ultrasonography, choledochoscopy, cholangioscopy, chromoendoscopy, confocal endoscopy, narrow-band imaging. MRI, CT, endoscopic ultrasonography, or 18FDG PET-CT cannot definitively demonstrate the stricture's neoplastic nature.

Treatment

Unfortunately, the outlook is bleak. Most patients have an advanced or incurable illness when they are diagnosed, leaving systemic therapy as their sole choice for treatment. It is generally known that subgroups vary in their tumor biology and clinical presentation in addition to their varied etiological sources. Surgery may be curative for individuals with resectable illness when they first arrive, although these patients make up a small percentage with substantial recurrence rates. Additionally, the recurrence patterns often prohibit additional curative resection.

The best method for extending survival is still total surgical resection (R0); however, disease recurrence is not unheard of. Furthermore, patient comorbidities sometimes precluded surgical intervention, even if it could technically be done. Therefore, in order to increase survival in such a population, reduced morbidity interventional procedures must be developed.

Surgery with complete resection represents the only treatment for CCA with curative intent. Other treatment approaches may include liver transplantation which is associated with rapid tumor recurrence and low survival, and it has historically not been recommended as a treatment for unresectable CCA. Chemotherapy for patients presenting with unresectable or metastatic CCA, systemic chemotherapy remains the mainstay palliative treatment modality, and the role of adjuvant chemotherapy is not clearly defined in CCA, but for patients with local recurrence after resectioning pCCA, chemotherapy has been recommended.

Cholangiocarcinoma (CCA) Epidemiology

The Cholangiocarcinoma epidemiology division provides insights about historical and current Cholangiocarcinoma patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as Cholangiocarcinoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

In the year 2021, the total diagnosed incident cases of CCA were 46,466 in the 7MM which are expected to grow during the study period, i.e., 2019-2032.

The disease epidemiology covered in the report provides historical as well as forecasted Cholangiocarcinoma epidemiology [segmented as Total Diagnosed-incidence Cases of Cholangiocarcinoma, Total Type-specific Cases of Cholangiocarcinoma, Total Age-specific Cases of Cholangiocarcinoma, Total Stage-specific Cases of Cholangiocarcinoma, Total Mutation-specific Cases of Cholangiocarcinoma, and Total Treated Cases (across lines) of Cholangiocarcinoma] in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Cholangiocarcinoma (CCA) Epidemiology

The epidemiology segment also provides the Cholangiocarcinoma epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

According to the DelveInsight, in the year 2021, the total diagnosed incident cases of CCA were 10,034 in the United States which are expected to grow during the study period, i.e., 2019-2032.

The highest number of total incident cases of CCA was observed in Italy among the EU5 countries with 6,489 cases in 2021 which are expected to grow during the study period, i.e., 2019-2032.

In the year 2021, the total diagnosed incident cases of CCA were 16,004 in Japan which are expected to grow during the study period, i.e., 2019-2032.

Cholangiocarcinoma (CCA) Drug Chapters

The drug chapter segment of the Cholangiocarcinoma report encloses the detailed analysis of Cholangiocarcinoma marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Cholangiocarcinoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Cholangiocarcinoma treatment.

Cholangiocarcinoma (CCA) Market Outlook

The Cholangiocarcinoma (CCA) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Cholangiocarcinoma market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

This segment gives a thorough detail of Cholangiocarcinoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Cholangiocarcinoma market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings

The Cholangiocarcinoma market size in the 7MM is expected to change during the study period 2019-2032. The therapeutic market of Cholangiocarcinoma in the seven major markets is expected to increase during the study period (2019-2032). In 2021, the total market size of Cholangiocarcinoma was USD 786.1 million which is expected to rise during the study period (2019-2032).

The United States Market Outlook

The total market size of Cholangiocarcinoma in the United States accounted for USD 237.3 million in 2021 which is expected to rise during the study period (2019-2032).

EU-5 Countries: Market Outlook

In EU-5, the total market size of Cholangiocarcinoma was USD 326 million in 2021, which is expected to rise during the study period (2019-2032).

Japan Market Outlook

In Japan, the total market size of Cholangiocarcinoma was USD 165.5 million in 2021, which is expected to rise during the study period (2019-2032).

Cholangiocarcinoma (CCA) Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Cholangiocarcinoma market or expected to get launched in the market during the study period 2019-2032. The analysis covers Cholangiocarcinoma market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Cholangiocarcinoma (CCA) Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Cholangiocarcinoma key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisition, and merger, licensing patent details, and other information for Cholangiocarcinoma emerging therapies.

Reimbursement Scenario in Cholangiocarcinoma (CCA)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Cholangiocarcinoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Cholangiocarcinoma market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitively and Market Intelligence analysis of the Cholangiocarcinoma (cUTI) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Cholangiocarcinoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies

• Comprehensive insight has been provided into the Cholangiocarcinoma epidemiology and treatment in the 7MM

• Additionally, an all-inclusive account of both the current and emerging therapies for Cholangiocarcinoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

• A detailed review of the Cholangiocarcinoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Cholangiocarcinoma market.

Report Highlights:

• In the coming years, the Cholangiocarcinoma market is set to change due to the upcoming therapies with novel route of administrations which are under investigation and ongoing research in the CCA; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

• The companies and academics are working to assess challenges and seek opportunities that could influence Cholangiocarcinoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• Major players are involved in developing therapies for Cholangiocarcinoma. The launch of emerging therapies will significantly impact the Cholangiocarcinoma market.

• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Cholangiocarcinoma.

• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Cholangiocarcinoma (CCA) Report Insights

• Patient Population
• Therapeutic Approaches
• Cholangiocarcinoma (CCA) Pipeline Analysis
• Cholangiocarcinoma (CCA) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Cholangiocarcinoma (CCA) Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Cholangiocarcinoma (CCA) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Cholangiocarcinoma (CCA) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

Key Questions

Market Insights:

• What was the Cholangiocarcinoma drug class share (%) distribution in 2019 and how it would look like in 2032?

• What would be the Cholangiocarcinoma total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?

• What are the key findings of the market across 7MM and which country will have the largest Cholangiocarcinoma market size during the forecast period (2019-2032)?

• At what CAGR, the Cholangiocarcinoma market is expected to grow by 7MM during the forecast period (2019-2032)?

• What would be the Cholangiocarcinoma market outlook across the 7MM during the forecast period (2019-2032)?

• What would be the Cholangiocarcinoma market growth till 2032, and what will be the resultant market Size in the year 2032?

• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Cholangiocarcinoma?

• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU-5 (Germany, Spain, France, Italy, UK), and Japan?

• What is the historical Cholangiocarcinoma patient pool in seven major markets covering the United States, EU-5 (Germany, Spain, France, Italy, UK), and Japan?

• What would be the forecasted patient pool of Cholangiocarcinoma in seven major markets covering the United States, EU-5 (Germany, Spain, France, Italy, UK), and Japan?

• Where will be the growth opportunities in the 7MM concerning the patient population about Cholangiocarcinoma?

• Out of all 7MM countries, which country would have the highest prevalent population of Cholangiocarcinoma during the forecast period (2019-2032)?

• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the Cholangiocarcinoma treatment in addition to the approved therapies?

• What are the current treatment guidelines for the treatment of Cholangiocarcinoma in the USA, Europe, and Japan?

• What are the Cholangiocarcinoma marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?

• How many companies are developing therapies for the treatment of Cholangiocarcinoma?

• How many therapies are in-development by each company for Cholangiocarcinoma treatment?

• How many are emerging therapies in mid-stage, and late stage of development for Cholangiocarcinoma treatment?

• What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cholangiocarcinoma therapies?

• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?

• What are the clinical studies going on for Cholangiocarcinoma and their status?

• What are the current challenges faced in drug development?

• What are the key designations that have been granted for the emerging therapies for Cholangiocarcinoma?

• What are the global historical and forecasted markets of Cholangiocarcinoma?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Cholangiocarcinoma market

• To understand the future market competition in the Cholangiocarcinoma market and Insightful review of the key market drivers and barriers

• Organize sales and marketing efforts by identifying the best opportunities for Cholangiocarcinoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan

• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors

• Organize sales and marketing efforts by identifying the best opportunities for the Cholangiocarcinoma market

• To understand the future market competition in the Cholangiocarcinoma Infection market

Table of Contents

1. Key Insights

2. Executive Summary of Cholangiocarcinoma (CCA)

3. Cholangiocarcinoma (CCA) Market Overview at a Glance

• 3.1. Total Market Share (%) Distribution of CCA in 2019
• 3.2. Total Market Share (%) Distribution of CCA in 2032

4. Cholangiocarcinoma (CCA): Disease Background and Overview

• 4.1. Introduction
• 4.2. Cholangiocarcinoma (CCA)
• 4.3. Symptoms of CCA
• 4.4. Classifications of Cholangiocarcinoma
• 4.5. Molecular pathogenesis of intrahepatic Cholangiocarcinoma
• 4.6. Diagnosis of CCA
  • 4.6.1. Algorithm for the diagnosis of CCA
  • 4.6.2. Staging of Intrahepatic CCA (ICCA)

5. Treatment

• 5.1. Treatment algorithm for Cholangiocarcinoma
• 5.2. Guidelines for the treatment of Cholangiocarcinoma
• 5.3. International Liver Cancer Association (ILCA) Guidelines for the Treatment of ICCA
• 5.4. NCCN Clinical Practice Guidelines- Hepatobiliary Cancers (Version 5.2020)

6. Epidemiology and Patient Population

• 6.1. Key Findings
• 6.2. Epidemiology Methodology
• 6.3. Incident Cases of Cholangiocarcinoma (CCA) in the 7MM

7. United States Epidemiology

• 7.1. Assumptions and Rationale
• 7.2. Incident Cases of Cholangiocarcinoma (CCA) in the United States
• 7.3. Type-specific Incident Cases of CCA in the United States
• 7.4. Age-specific Incident Cases of CCA in the United States
• 7.5. Stage-specific Incident Cases of CCA in the United States
• 7.6. Biomarker-specific Incident Cases of CCA in the United States

8. EU5 Epidemiology

• 8.1. Assumptions and Rationale
• 8.2. Incident Cases of Cholangiocarcinoma (CCA) in EU-5
• 8.3. Type-specific Incident Cases of CCA in EU-5
• 8.4. Age-specific Incident Cases of CCA in EU-5
• 8.5. Stage-specific Incident Cases of CCA in EU-5
• 8.6. Biomarker-specific Incident Cases of CCA in EU-5

9. Japan Epidemiology

• 9.1. Assumptions and Rationale
• 9.2. Incident Cases of CCA in Japan
• 9.3. Type-specific Incident Cases of CCA in Japan
• 9.4. Age-specific Incident Cases of CCA in Japan
• 9.5. Stage-specific Incident Cases of CCA in Japan
• 9.6. Biomarker-specific Incident Cases of CCA in Japan

10. Patient Journey

11. Key endpoints in Cholangiocarcinoma trials

12. Marketed Drugs

• 12.1. Pemazyre (Pemigatinib): Incyte Corporation
  • 12.1.1. Drug Description
  • 12.1.2. Regulatory Milestones
  • 12.1.3. Other Developmental Activities
  • 12.1.4. Advantages and Disadvantages
  • 12.1.5. Clinical Development
  • 12.1.6. Safety and Efficacy
  • 12.1.7. Product Profile
• 12.2. Infigratinib (Truseltiq): Roche
  • 12.2.1. Product Description
  • 12.2.2. Regulatory Milestones
  • 12.2.3. Other Developmental Activities
  • 12.2.4. Advantages and Disadvantages
  • 12.2.5. Clinical Development
  • 12.2.6. Safety and Efficacy
  • 12.2.7. Product Profile
• 12.2. Tibsovo (ivosidenib): Agios Pharmaceuticals/ Servier Pharmaceuticals
  • 12.2.1. Product Description
  • 12.2.2. Regulatory Milestones
  • 12.2.3. Other Developmental Activities
  • 12.2.4. Advantages and Disadvantages
  • 12.2.5. Clinical Development
  • 12.2.6. Safety and Efficacy
  • 12.2.7. Product Profile

13. Emerging Therapies

• 13.1. Imfinzi (durvalumab): (AstraZeneca)
  • 13.1.1. Drug Description
  • 13.1.2. Other Developmental Activities
  • 13.1.3. Clinical Development
  • 13.1.4. Safety and Efficacy
  • 13.1.5. Product Profile
• 13.2. Melphalan: Decalth Systems
  • 13.2.1. Drug Description
  • 13.2.2. Other Developmental Activities
  • 13.2.3. Clinical Development
  • 13.2.4. Safety and Efficacy
  • 13.2.5. Product Profile
• 13.3. Derazantinib: Basilea Pharmaceutica
  • 13.3.1. Drug Description
  • 13.3.2. Other Developmental Activities
  • 13.3.3. Clinical Development
  • 13.3.4. Safety and Efficacy
  • 13.3.5. Product Profile
• 13.4. TAS-120 (futibatinib): Taiho Oncology
  • 13.4.1 Drug Description
  • 13.4.2. Other Developmental Activities
  • 13.4.3. Clinical Development
  • 13.4.4. Safety and Efficacy
  • 13.4.5. Product Profile
• 13.5. E7090: Eisai Pharmaceuticals
  • 13.5.1. Drug Description
  • 13.5.2. Other Developmental Activities
  • 13.5.3. Clinical Development
  • 13.5.4. Safety and Efficacy
  • 13.5.5. Product Profile
• 13.6. TT-00420: TransThera Sciences
  • 13.6.1. Drug Description
  • 13.6.2. Other Developmental Activities
  • 13.6.3. Clinical Development
  • 13.6.4. Safety and Efficacy
  • 13.6.5. Product Profile

14. Conjoint Analysis

15. Cholangiocarcinoma (CCA): 7MM Market Analysis

• 15.1. Key Findings
• 15.2. Market Outlook
• 15.3. Market Size of Cholangiocarcinoma (CCA) in the 7MM
  • 15.3.1. Total Market Size of Cholangiocarcinoma (CCA) by therapies in the 7MM
  • 15.3.2. Market Size by Therapies for Early stage disease in the 7MM
  • 15.3.3. Market Size by Therapies in First Line Advanced and Metastatic Cases in the 7MM
  • 15.3.4. Market Size by Therapies in Second Line Advanced and Metastatic Cases in the 7MM
• 15.4. Total Market size of Cholangiocarcinoma (CCA) in the US
  • 15.4.1. Market Size by Therapies for Early stage disease in the US
  • 15.4.2. Market Size by Therapies in First Line Advanced and Metastatic Cases in the US
  • 15.4.3. Market Size by Therapies in Second Line Advanced and Metastatic Cases in the US
• 15.5. Total Market size of Cholangiocarcinoma (CCA) in EU-5
  • 15.5.1. Market Size by Therapies for Early stage disease in EU-5
  • 15.5.2. Market Size by Therapies in First Line Advanced and Metastatic Cases in EU-5
  • 15.5.3. Market Size by Therapies in Second Line Advanced and Metastatic Cases in EU-5
• 15.6. Total Market size of Cholangiocarcinoma (CCA) in Japan
  • 15.6.1. Market Size by Therapies for Early stage disease in Japan
  • 15.6.2. Market Size by Therapies in First Line Advanced and Metastatic Cases in Japan
  • 15.6.3. Market Size by Therapies in Second Line Advanced and Metastatic Cases in Japan

16. Market Access and Reimbursement

• 16.1. Reimbursement
• 16.2. Key HTA decisions
• 16.3. Patient Access Program

17. KOL views

18. Market Drivers

19. Market Barriers

20. SWOT Analysis

21. Unmet needs

22. Appendix

• 22.1. Bibliography
• 22.2. Report Methodology

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight